Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. OncoSil Medical Limited
  6. Summary
    OSL   AU000000OSL3

ONCOSIL MEDICAL LIMITED

(OSL)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
0.044 0.045 0.047 0.045 0.046 Last
6264629 1686683 1111642 1773740 714289 Volume
-8.33% +2.27% +4.44% -4.26% +2.22% Change
Estimated financial data (e)
Sales 2022 - - -
Net income 2022 -6,56 M -4,76 M -4,76 M
Net cash position 2022 17,4 M 12,6 M 12,6 M
P/E ratio 2022 -5,82x
Yield 2022 -
Sales 2023 0,71 M 0,52 M 0,52 M
Net income 2023 -6,93 M -5,03 M -5,03 M
Net cash position 2023 32,8 M 23,8 M 23,8 M
P/E ratio 2023 -6,71x
Yield 2023 -
Capitalization 36,4 M 26,4 M 26,5 M
EV / Sales 2022 -
EV / Sales 2023 5,18x
Nbr of Employees -
Free-Float 79,2%
More Financials
Company
OncoSil Medical Limited is an Australian- based biotechnology company. The Company is focused on unresectable locally advanced pancreatic cancer (LAPC). The Company's lead product, OncoSil, which is a single-use brachytherapy internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. The OncoSil consists of microparticles that contain a radioisotope... 
More about the company
All news about ONCOSIL MEDICAL LIMITED
08/18OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
07/19OncoSil Medical Limited Announces Board Changes
CI
06/02OncoSil Medical Limited Provides Update on TGA Regulatory
CI
05/04ONCOSIL MEDICAL : Receives Regulatory Clearance for Oncological Device in Hong Kong
MT
05/03OncoSil Medical Limited Receives Regulatory Approval from Hong Kong
CI
03/21ONCOSIL MEDICAL LIMITED(ASX : OSL) dropped from S&P/ASX Emerging Companies Index
CI
02/28OncoSil Medical Limited Announces Change of Registered Office and Principal Place of Bu..
CI
02/23ONCOSIL MEDICAL : Widens Net Loss in Fiscal H1 on Device Commercialization Activities; Sha..
MT
02/22Oncosil Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2..
CI
02/10OncoSil Medical Limited Announces Executive Appointments
CI
01/21OncoSil Medical Limited Appoints Nigel Lange as Chief Executive Officer
CI
01/18Oncosil Medical Limited Reports Unaudited Sales Results for the Half Year Ended 31 Dece..
CI
2020ONCOSIL MEDICAL : Sinks 12% on CEO Termination
MT
2020OncoSil Medical Limited Announces Executive Changes
CI
2020OncoSil Medical Limited Announces Executive Changes
CI
More news
News in other languages on ONCOSIL MEDICAL LIMITED

- No features available -

More news
Chart ONCOSIL MEDICAL LIMITED
Duration : Period :
OncoSil Medical Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCOSIL MEDICAL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,05 AUD
Average target price 0,11 AUD
Spread / Average Target 145%
EPS Revisions
Managers and Directors
Nigel Lange Chief Executive Officer, MD & Director
Karl David Pechmann Chief Financial Officer & Secretary
Christopher Graham Roberts Executive Chairman
Ralph Peters Chief Medical Officer
Martin Cross Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ONCOSIL MEDICAL LIMITED-61.67%26
MODERNA, INC.335.15%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.38%50 254
CELLTRION, INC.-23.54%33 124
SEAGEN INC.-5.09%30 241